Comparative in vitro potency of gemifloxacin against European respiratory tract pathogens isolated in the Alexander Project

A. Marchese, E. A. Debbia, G. C. Schito

Research output: Contribution to journalArticlepeer-review

Abstract

European isolates collected in 1998 for the Alexander Project were tested for their susceptibility to ciprofloxacin, ofloxacin and a novel fluoroquinolone, gemifloxacin, which has a spectrum of activity including common and atypical respiratory pathogens. MIC90s of gemifloxacin for Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis were 0.03, 0.06 and 0.015 mg/L, respectively. On the basis of MIC90s, gemifloxacin was the most potent antimicrobial tested against S. pneumoniae and M. catarrhalis. Against H. influenzae, gemifloxacin was one tube dilution more potent than ofloxacin and one tube dilution less potent than ciprofloxacin. As resistance to currently available antimicrobial agents increases, gemifloxacin offers potential as a promising new agent for the treatment of respiratory tract infection.

Original languageEnglish
Pages (from-to)11-15
Number of pages5
JournalJournal of Antimicrobial Chemotherapy
Volume46
Issue numberTOPIC T1
Publication statusPublished - 2000

ASJC Scopus subject areas

  • Microbiology
  • Pharmacology

Fingerprint Dive into the research topics of 'Comparative in vitro potency of gemifloxacin against European respiratory tract pathogens isolated in the Alexander Project'. Together they form a unique fingerprint.

Cite this